Engineering large-scale chromosomal deletions by CRISPR-Cas9

por Eleveld, Thomas F, Bakali, Chaimaa, Eijk, Paul P, Stathi, Phylicia, Vriend, Lianne E, Poddighe, Pino J, Ylstra, Bauke
Publicado 2021

The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors

por Timmerman, Dennis M., Eleveld, Thomas F., Gillis, Ad J. M., Friedrichs, Carlijn C., Hillenius, Sanne, Remmers, Tessa L., Sriram, Sruthi, Looijenga, Leendert H. J.
Publicado 2021

Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers

por Schubert, Nil A., Lowery, Caitlin D., Bergthold, Guillaume, Koster, Jan, Eleveld, Thomas F., Rodríguez, Ana, Jones, David T.W., Vassal, Gilles, Stancato, Louis F., Pfister, Stefan M., Caron, Hubert N., Molenaar, Jan J.
Publicado 2020

Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors

por Timmerman, Dennis M., Eleveld, Thomas F., Sriram, Sruthi, Dorssers, Lambert C.J., Gillis, Ad J.M., Schmidtova, Silvia, Kalavska, Katarina, van de Werken, Harmen J.G., Oing, Christoph, Honecker, Friedemann, Mego, Michal, Looijenga, Leendert H.J.
Publicado 2022

Recurrence of a Mediastinal Germ-Cell Tumor as a Somatic-Type Malignancy: A Complex Case Report

por Hulsker, Caroline C. C., Kranendonk, Mariëtte E. G., Eleveld, Thomas F., Gillis, Ad J. M., van de Ven, Cornelis P., van Eijkelenburg, Natasha K. A., van der Kaaij, Niels P., van der Steeg, Alida F. W., Looijenga, Leendert H. J.
Publicado 2021

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

por Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R.
Publicado 2022

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

por Eleveld, Thomas F., Vernooij, Lindy, Schild, Linda, Koopmans, Bianca, Alles, Lindy K., Ebus, Marli E., Dandis, Rana, van Tinteren, Harm, Caron, Huib N., Koster, Jan, van Noesel, Max M., Tytgat, Godelieve A. M., Eising, Selma, Versteeg, Rogier, Dolman, M. Emmy M., Molenaar, Jan J.
Publicado 2023